Dutasteride

• CAT Number: A001014
• CAS Number: 164656-23-9
• Molecular Formula: C27H30F6N2O2
• Molecular Weight: 528.50
• Purity: ≥95%
• Synonyms: 164656-23-9; Avodart; Avolve; GG-745; Duagen
• Target: Apoptosis
• Solubility: >26.4mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
• InChI: InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
• InChIKey: JWJOTENAMICLJG-QWBYCMEYSA-N
• SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C

Dutasteride（Cat No.:A001014）is a synthetic 5-alpha-reductase inhibitor used primarily to treat benign prostatic hyperplasia (BPH) by reducing the size of an enlarged prostate. It works by inhibiting both type I and type II 5-alpha-reductase enzymes, which convert testosterone into dihydrotestosterone (DHT), a hormone linked to prostate growth. By lowering DHT levels, dutasteride alleviates symptoms of BPH, such as urinary retention and difficulty urinating. It has also been investigated for its role in treating male pattern baldness. Dutasteride is known for its effectiveness in managing prostate-related conditions.

Reference

1: Ino H, Itoh H, Doi Y, Igarashi H, Numachi Y. Evaluation of Bioequivalence
Between 0.5-mg Dutasteride Capsules Manufactured by GlaxoSmithKline and an
Existing Formulation: A Randomized Study in Healthy Japanese Male Volunteers.
Clin Pharmacol Drug Dev. 2017 Dec 28. doi: 10.1002/cpdd.407. [Epub ahead of
print] PubMed PMID: 29283507.

2: Gupta AK, Carviel J, Gupta MA, Shear NH. Assessing dutasteride-associated
sexual dysfunction using the U.S. Food and Drug Administration Adverse Event
Reporting System. J Eur Acad Dermatol Venereol. 2017 Dec 1. doi:
10.1111/jdv.14728. [Epub ahead of print] PubMed PMID: 29194783.

3: Prasaja B, Harahap Y, Lusthom W, Yumi L, Sofiana A, Sandra M, Safira F, Chilmi
U. Impact of Truncated Area on Point Estimate and Intra-Subject Variability in
Bioequivalence of Dutasteride with Long Half-Life. Drug Res (Stuttg). 2017 Nov
20. doi: 10.1055/s-0043-121695. [Epub ahead of print] PubMed PMID: 29156456.

4: Demirbas A, Resorlu B, Gulpinar MT, Kardas S, Doluoglu OG, Tepeler A, Kilinc
MF, Karakan T, Ozcan S. Does Preoperative Use of Dutasteride Decrease Bleeding
During Open Prostatectomy? Urol J. 2017 Nov 15. doi: 10.22037/uj.v0i0.3693. [Epub
ahead of print] PubMed PMID: 29150830.

5: Shigehara K, Mizokami A. Editorial Comment to Influence of dutasteride
treatment on serum hormone levels and aging male symptoms in patients with benign
prostatic enlargement. Int J Urol. 2017 Oct 23. doi: 10.1111/iju.13477. [Epub
ahead of print] PubMed PMID: 29057558.

6: Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC,
Karanastasis D, Plastino J, Giuliano F, Rosen RC. A prospective randomised
placebo-controlled study of the impact of dutasteride/tamsulosin combination
therapy on sexual function domains in sexually active men with lower urinary
tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int.
2017 Oct 16. doi: 10.1111/bju.14057. [Epub ahead of print] PubMed PMID: 29044968.

7: Litim N, Morissette M, Caruso D, Melcangi RC, Di Paolo T. Effect of the
5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian
mice. J Steroid Biochem Mol Biol. 2017 Nov;174:242-256. doi:
10.1016/j.jsbmb.2017.09.021. Epub 2017 Oct 2. PubMed PMID: 28982631.

8: Maeda T, Kikuchi E, Hasegawa M, Homma K, Ando T, Suzuki K, Kaneko G, Mizuno R,
Miyajima A, Oya M. Influence of dutasteride treatment on serum hormone levels and
aging male symptoms in patients with benign prostatic enlargement. Int J Urol.
2017 Oct 3. doi: 10.1111/iju.13470. [Epub ahead of print] PubMed PMID: 28975673.

9: Saceda-Corralo D, Rodrigues-Barata AR, Vañó-Galván S, Jaén-Olasolo P.
Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. Int J
Trichology. 2017 Jul-Sep;9(3):143-145. doi: 10.4103/ijt.ijt_73_16. PubMed PMID:
28932074; PubMed Central PMCID: PMC5596657.

10: Kaplan SA. Re: Rates of Prostate Surgery and Acute Urinary Retention for
Benign Prostatic Hyperplasia in Men Treated with Dutasteride or Finasteride. J
Urol. 2017 Oct;198(4):719-721. doi: 10.1016/j.juro.2017.07.003. Epub 2017 Jul 7.
PubMed PMID: 28905745.